TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vanda ( (VNDA) ) just unveiled an announcement.
On November 28, 2025, Vanda Pharmaceuticals announced updates regarding its drug tradipitant for motion sickness. The FDA requested, and Vanda agreed to, a brief extension for the expedited re-review of the partial clinical hold on long-term studies, now set to complete by December 5, 2025. Additionally, the FDA issued labeling comments, initiating formal discussions for the New Drug Application of tradipitant, with a PDUFA target action date of December 30, 2025. These developments are crucial as Vanda aims to introduce the first new pharmacologic treatment for motion sickness in over four decades, potentially impacting the company’s market position and offering new solutions for stakeholders.
The most recent analyst rating on (VNDA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Vanda stock, see the VNDA Stock Forecast page.
Spark’s Take on VNDA Stock
According to Spark, TipRanks’ AI Analyst, VNDA is a Neutral.
Vanda Pharmaceuticals’ overall stock score reflects significant financial challenges, weak technical indicators, and unattractive valuation. Despite potential growth from new products and corporate events, operational inefficiencies and regulatory challenges weigh heavily on the stock.
To see Spark’s full report on VNDA stock, click here.
More about Vanda
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs, improving patients’ lives. The company is involved in the clinical development of tradipitant, a neurokinin-1 receptor antagonist, for various indications including gastroparesis, motion sickness, and prevention of nausea and vomiting induced by GLP-1 receptor agonists.
Average Trading Volume: 658,858
Technical Sentiment Signal: Buy
Current Market Cap: $313.2M
For an in-depth examination of VNDA stock, go to TipRanks’ Overview page.